HRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Heron Therapeutics Inc (HRTX) is not a good buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, the options data suggests a lack of strong bullish sentiment, and there are no significant positive catalysts or recent news to support a strong upward movement. While the financial performance shows improvement in revenue and net income, the company is still operating at a loss, and the stock's short-term trend suggests limited upside potential.
The technical indicators for HRTX are bearish. The MACD is negatively expanding below zero, the RSI is neutral at 23.198, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 1.149), with resistance levels at R1: 1.386 and R2: 1.459. Overall, the trend suggests downward pressure.
The company's financials for Q3 2025 show improvement in revenue (+16.47% YoY) and net income (+260.87% YoY), along with a significant increase in EPS (+233.33% YoY).
No recent news or significant events to drive the stock upward. Gross margin dropped by -3.30% YoY, and the company remains unprofitable. The stock's short-term trend indicates limited upside potential, with a 40% chance of only a 0.52% gain in the next day and a potential decline of -3.79% in the next month.
In Q3 2025, the company reported revenue of $38.213M (+16.47% YoY), net income of -$17.495M (improved by +260.87% YoY), and EPS of -0.1 (+233.33% YoY). Gross margin decreased to 68.82 (-3.30% YoY). While the financials show improvement, the company is still operating at a loss.
No recent analyst rating or price target changes were provided. Wall Street sentiment is neutral, with no strong buy or sell signals.
